Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyinosine-polycytidylic acid is a **synthetic double-stranded polyribonucleotide** comprised of one polymer strand of inosinic acid and one of cytidylic acid. It acts as a **synthetic analog of viral double-stranded RNA** and is a potent immunostimulant, widely used in immunological research and as an adjuvant. Poly(I:C) potently activates **Toll-like receptor 3 (TLR3)**, which is found mainly in endosomal membranes of immune cells such as dendritic cells, macrophages, and B cells. By mimicking viral infection, it induces **innate immune responses**, leading to production of **type I interferons (IFN-α, IFN-β)** and proinflammatory cytokines, and activates endothelial cells to express adhesion molecules and chemokines that promote leukocyte recruitment. It is investigated for use as a vaccine adjuvant, as an immunomodulator, and in cancer therapy, but systemic use is limited by toxicity. Variants such as polyICLC (Hiltonol) are used in clinical trials for improved stability and tolerability[1][2][5][8][9].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyinosine-polycytidylic acid.